Global fecal occult blood testing market is projected to register a substantial CAGR of 5.3 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Fecal Occult Blood Tests Market, By Test Type (Lateral Flow Immuno-Fob Test Kits, Immuno-FOB Agglutination Test Kits, Immuno-FOB ELISA Test Kits, Guaiac FOB Stool Test, Flushable Reagent Pad or Tissue, and Others), By Application (Colorectal Cancer Screening, Concern for Gastrointestinal Bleeding, Polyps, Diverticulosis, Ulcers, Haemorrhoids, Colitis, Anemia, and Others), By End User (Diagnostic Laboratories, Hospitals, Speciality Clinics, and Others), By Distribution Channel (Direct Sales, Retail Sales, E-Commerce, and Others), Region (Global, Europe, Asia-Pacific, South America, and Middle East and Africa), Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the Global fecal occult blood testing market are:
Rising cases of colorectal cancer globally
Development of direct-to-consumer laboratory testing
Increasing inclination towards point-of-care diagnostics
Easy availability of fecal occult immunological test devices in online stores
Market Players
Some of the key market players for the global fecal occult blood testing market are listed below:
Quidel Corporation
Siemens Healthcare GmbH
Biohit Oyj
Accubiotech Co.Ltd.
Accuquik Test Kits
Aidian
Alfa Scientific Designs, Inc.
Apacor Limited
Others
TABLE OF CONTENTS
1 INTRODUCTION 75
- 1.1 OBJECTIVES OF THE STUDY 75
- 1.2 MARKET DEFINITION 75
- 1.3 OVERVIEW OF THE GLOBAL FECAL OCCULT BLOOD TESTS MARKET 75
- 1.4 CURRENCY AND PRICING 77
- 1.5 LIMITATIONS 77
- 1.6 MARKETS COVERED 77
2 MARKET SEGMENTATION 81
- 2.1 MARKETS COVERED 81
- 2.2 GEOGRAPHICAL SCOPE 82
- 2.3 YEARS CONSIDERED FOR THE STUDY 83
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 84
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
- 2.6 MULTIVARIATE MODELLING 88
- 2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 88
- 2.8 MARKET APPLICATION COVERAGE GRID 89
- 2.9 DBMR MARKET POSITION GRID 90
- 2.10 VENDOR SHARE ANALYSIS 91
- 2.11 SECONDARY SOURCES 92
- 2.12 ASSUMPTIONS 92
3 EXECUTIVE SUMMARY 93
4 PREMIUM INSIGHTS 95
- 4.1 PESTEL ANALYSIS 98
- 4.2 PORTER'S 5 FORCES 99
5 INDUSTRY INSIGHTS 100
6 REGULATORY FRAMEWORK 102
- 6.1 REGULATORY SCENARIO BY U.S. FDA 102
- 6.2 REGULATORY SCENARIO IN U.S. 102
- 6.3 REGULATORY SCENARIO IN EUROPE 103
- 6.4 REGULATORY SCENARIO IN CANADA 103
- 6.5 REGULATORY SCENARIO IN AUSTRALIA 103
7 MARKET OVERVIEW 104
- 7.1 DRIVERS 106
- 7.1.1 RISING CASES OF COLORECTAL CANCER GLOBALLY 106
- 7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING 106
- 7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES 107
- 7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS 107
- 7.2 RESTRAINTS 107
- 7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES 107
- 7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES 108
- 7.3 OPPORTUNITIES 108
- 7.3.1 INCREASE IN SCREENING PROCEDURES 108
- 7.3.2 RISING TECHNICAL ADVANCEMENTS 109
- 7.3.3 STRATEGIC INITIATIVES 109
- 7.4 CHALLENGES 110
- 7.4.1 LACK OF SKILLED PROFESSIONALS 110
- 7.4.2 LOW EFFICIENCY 110
8 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE 111
- 8.1 OVERVIEW 112
- 8.2 LATERAL FLOW IMMUNO-FOB TEST KITS 115
- 8.3 IMMUNO-FOB AGGLUTINATION TEST KITS 115
- 8.4 IMMUNO-FOB ELISA TEST KITS 116
- 8.5 GUAIAC FOB STOOL TEST 117
- 8.5.1 KITS 118
- 8.5.1.1 GUAIAC SLIDES 118
- 8.5.1.1.1 25 PACKAGE 118
- 8.5.1.1.2 20 PACKAGE 118
- 8.5.1.1.3 OTHERS 118
- 8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER 119
- 8.5.1.2.1 SENSITIVITY IS 50NG/ML 119
- 8.5.1.2.1.1 25 PACKAGE 119
- 8.5.1.2.1.2 20 PACKAGE 119
- 8.5.1.2.1.3 OTHERS 120
- 8.5.1.2.2 SENSITIVITY IS 75NG/ML 120
- 8.5.1.2.2.1 25 PACKAGE 120
- 8.5.1.2.2.2 20 PACKAGE 120
- 8.5.1.2.2.3 OTHERS 120
- 8.5.1.2.3 OTHERS 120
- 8.5.1.3 OTHERS 121
- 8.5.2 REAGENTS 121
- 8.5.2.1 HYDROGEN PEROXIDE 121
- 8.5.2.2 OTHERS 121
- 8.6 FLUSHABLE REAGENT PAD OR TISSUE 121
- 8.7 OTHERS 122
9 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION 123
- 9.1 OVERVIEW 124
- 9.2 COLORECTAL CANCER SCREENING 127
- 9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS 128
- 9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS 128
- 9.2.3 IMMUNO-FOB ELISA TEST KITS 128
- 9.2.4 GUAIAC FOB STOOL TEST 128
- 9.2.5 FLUSHABLE REAGENT PAD OR TISSUE 128
- 9.2.6 OTHERS 128
- 9.3 CONCERN FOR GASTROINTESTINAL BLEEDING 128
- 9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS 129
- 9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS 129
- 9.3.3 IMMUNO-FOB ELISA TEST KITS 129
- 9.3.4 GUAIAC FOB STOOL TEST 130
- 9.3.5 FLUSHABLE REAGENT PAD OR TISSUE 130
- 9.3.6 OTHERS 130
- 9.4 POLYPS 130
- 9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS 131
- 9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS 131
- 9.4.3 IMMUNO-FOB ELISA TEST KITS 131
- 9.4.4 GUAIAC FOB STOOL TEST 131
- 9.4.5 FLUSHABLE REAGENT PAD OR TISSUE 131
- 9.4.6 OTHERS 131
- 9.5 DIVERTICULOSIS 132
- 9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS 133
- 9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS 133
- 9.5.3 IMMUNO-FOB ELISA TEST KITS 133
- 9.5.4 GUAIAC FOB STOOL TEST 133
- 9.5.5 FLUSHABLE REAGENT PAD OR TISSUE 133
- 9.5.6 OTHERS 133
- 9.6 ULCERS 133
- 9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS 134
- 9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS 134
- 9.6.3 IMMUNO-FOB ELISA TEST KITS 134
- 9.6.4 GUAIAC FOB STOOL TEST 135
- 9.6.5 FLUSHABLE REAGENT PAD OR TISSUE 135
- 9.6.6 OTHERS 135
- 9.7 HAEMORRHOIDS 135
- 9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS 136
- 9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS 136
- 9.7.3 IMMUNO-FOB ELISA TEST KITS 136
- 9.7.4 GUAIAC FOB STOOL TEST 136
- 9.7.5 FLUSHABLE REAGENT PAD OR TISSUE 136
- 9.7.6 OTHERS 136
- 9.8 COLITIS 137
- 9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS 138
- 9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS 138
- 9.8.3 IMMUNO-FOB ELISA TEST KITS 138
- 9.8.4 GUAIAC FOB STOOL TEST 138
- 9.8.5 FLUSHABLE REAGENT PAD OR TISSUE 138
- 9.8.6 OTHERS 138
- 9.9 ANEMIA 138
- 9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS 139
- 9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS 139
- 9.9.3 IMMUNO-FOB ELISA TEST KITS 139
- 9.9.4 GUAIAC FOB STOOL TEST 140
- 9.9.5 FLUSHABLE REAGENT PAD OR TISSUE 140
- 9.9.6 OTHERS 140
- 9.10 OTHERS 140
10 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY END USER 141
- 10.1 OVERVIEW 142
- 10.2 DIAGNOSTIC LABORATORIES 145
- 10.3 HOSPITALS 145
- 10.4 SPECIALITY CLINICS 146
- 10.5 OTHERS 147
11 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL 148
- 11.1 OVERVIEW 149
- 11.2 DIRECT TENDER 152
- 11.3 RETAIL SALE 152
- 11.4 E-COMMERCE 153
- 11.5 OTHERS 154
12 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY REGION 155
- 12.1 OVERVIEW 156
- 12.2 NORTH AMERICA 161
- 12.2.1 U.S. 174
- 12.2.2 CANADA 182
- 12.2.3 MEXICO 190
- 12.3 ASIA-PACIFIC 198
- 12.3.1 CHINA 211
- 12.3.2 JAPAN 219
- 12.3.3 INDIA 227
- 12.3.4 AUSTRALIA 235
- 12.3.5 SOUTH KOREA 243
- 12.3.6 THAILAND 252
- 12.3.7 SINGAPORE 260
- 12.3.8 INDONESIA 268
- 12.3.9 MALAYSIA 277
- 12.3.10 PHILIPPINES 286
- 12.3.11 REST OF ASIA-PACIFIC 295
- 12.4 EUROPE 296
- 12.4.1 GERMANY 311
- 12.4.2 FRANCE 321
- 12.4.3 U.K. 331
- 12.4.4 ITALY 341
- 12.4.5 SPAIN 351
- 12.4.6 RUSSIA 361
- 12.4.7 SWITZERLAND 371
- 12.4.8 NETHERLANDS 381
- 12.4.9 TURKEY 391
- 12.4.10 BELGIUM 401
- 12.4.11 REST OF EUROPE 411
- 12.5 SOUTH AMERICA 412
- 12.5.1 BRAZIL 427
- 12.5.2 ARGENTINA 437
- 12.5.3 REST OF SOUTH AMERICA 447
- 12.6 MIDDLE EAST AND AFRICA 448
- 12.6.1 SOUTH AFRICA 463
- 12.6.2 SAUDI ARABIA 473
- 12.6.3 U.A.E. 483
- 12.6.4 EGYPT 493
- 12.6.5 ISRAEL 503
- 12.6.6 REST OF MIDDLE EAST AND AFRICA 513
13 GLOBAL FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE 514
- 13.1 COMPANY SHARE ANALYSIS: GLOBAL 514
- 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 515
- 13.3 COMPANY SHARE ANALYSIS: EUROPE 516
- 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 517
14 SWOT ANALYSIS 518
15 COMPANY PROFILE 519
- 15.1 QUIDEL CORPORATION 519
- 15.1.1 COMPANY SNAPSHOT 519
- 15.1.2 REVENUE ANALYSIS 519
- 15.1.3 COMPANY SHARE ANALYSIS 520
- 15.1.4 PRODUCT PORTFOLIO 520
- 15.1.5 RECENT DEVELOPMENT 520
- 15.2 WONDFO. 521
- 15.2.1 COMPANY SNAPSHOT 521
- 15.2.2 COMPANY SHARE ANALYSIS 521
- 15.2.3 PRODUCT PORTFOLIO 522
- 15.2.4 RECENT DEVELOPMENT 522
- 15.3 SIEMENS HEALTHCARE GMBH 523
- 15.3.1 COMPANY SNAPSHOT 523
- 15.3.2 REVENUE ANALYSIS 523
- 15.3.3 COMPANY SHARE ANALYSIS 524
- 15.3.4 RODUCT PORTFOLIO 524
- 15.3.5 RECENT DEVELOPMENT 524
- 15.4 EIKEN CHEMICAL CO., LTD. 525
- 15.4.1 COMPANY SNAPSHOT 525
- 15.4.2 REVENUE ANALYSIS 525
- 15.4.3 COMPANY SHARE ANALYSIS 526
- 15.4.4 PRODUCT PORTFOLIO 526
- 15.4.5 RECENT DEVELOPMENT 526
- 15.5 BIOHIT OYJ 527
- 15.5.1 COMPANY SNAPSHOT 527
- 15.5.2 REVENUE ANALYSIS 527
- 15.5.3 COMPANY SHARE ANALYSIS 528
- 15.5.4 PRODUCT PORTFOLIO 528
- 15.5.5 RECENT DEVELOPMENT 528
- 15.6 ACCUBIOTECH CO LTD 529
- 15.6.1 COMPANY SNAPSHOT 529
- 15.6.2 PRODUCT PORTFOLIO 529
- 15.6.3 RECENT DEVELOPMENT 529
- 15.7 ACCUQUIK TEST KITS 530
- 15.7.1 COMPANY SNAPSHOT 530
- 15.7.2 PRODUCT PORTFOLIO 530
- 15.7.3 RECENT DEVELOPMENT 530
- 15.8 AIDIAN 531
- 15.8.1 COMPANY PROFILE 531
- 15.8.2 PRODUCT PORTFOLIO 531
- 15.8.3 RECENT DEVELOPMENT 531
- 15.9 ALFA SCIENTIFIC DESIGNS, INC. 532
- 15.9.1 COMPANY SNAPSHOT 532
- 15.9.2 PRODUCT PORTFOLIO 532
- 15.9.3 RECENT DEVELOPMENT 532
- 15.10 APACOR LIMITED 533
- 15.10.1 COMPANY SNAPSHOT 533
- 15.10.2 PRODUCT PORTFOLIO 533
- 15.10.3 RECENT DEVELOPMENT 533
- 15.11 BIOPANDA REAGENTS LTD 534
- 15.11.1 COMPANY SNAPSHOT 534
- 15.11.2 PRODUCT PORTFOLIO 534
- 15.11.3 RECENT DEVELOPMENT 534
- 15.12 BODITECH MED INC. 535
- 15.12.1 COMPANY SNAPSHOT 535
- 15.12.2 PRODUCT PORTFOLIO 535
- 15.12.3 RECENT DEVELOPMENT 535